Edward John Rebar is an American biologist, and is senior vice president and chief technology officer of Sana Biotechnology.[1]
Edward Rebar | |
|---|---|
| Born | Edward John Rebar |
| Alma mater |
|
| Known for | Zinc finger protein platform |
| Scientific career | |
| Fields |
|
| Institutions | Sana Biotechnology, Sangamo Therapeutics |
| Thesis | Selection studies of zinc finger-DNA recognition (1997) |
| Doctoral advisor | Carl Pabo |
Education
editEdward John Rebar earned a Bachelor of Science in biochemistry from Rutgers University. He completed a Doctor of Philosophy in biophysics and structural biology from Massachusetts Institute of Technology. His 1997 dissertation was titled Selection studies of zinc finger-DNA recognition. His doctoral advisor was Carl Pabo.[2] Rebar worked as a post-doctoral fellow at the University of California, Berkeley.[3]
Career
editRebar joined Sangamo Therapeutics in 1998. He worked on the zinc finger protein platform developed by the company. In 2018, Rebar replaced Michael C. Holmes as the senior vice president and chief technology officer of Sangamo.[3][4] In 2020, Rebar became the chief technology officer of Sana Biotechnology.[5]
References
edit- ^ "Sana Biotechnology Strengthens Senior Research Leadership Team with Ed Rebar, Ph.D. and Terry Fry, M.D." PR Newswire. Retrieved May 26, 2023.
- ^ Rebar, Edward John (1997). Selection studies of zinc finger-DNA recognition (Thesis). OCLC 37525775.
- ^ a b "Sangamo Therapeutics appoints Edward Rebar as senior vice president". Post Online Media. Richmond, California. July 16, 2018. Retrieved October 1, 2018.
- ^ Hale, Conor (July 20, 2018). "Chutes & Ladders: Sangamo loses another top executive". FierceBiotech. Retrieved February 11, 2019.
- ^ "Sana Biotechnology Strengthens Senior Research Leadership Team with Ed Rebar, Ph.D. and Terry Fry, M.D." PR Newswire. Retrieved May 26, 2023.